20.5 C
New York
Wednesday, June 3, 2026

Tag: tablets

newssourceFORcompanyinformationcontent1marketreleases

Nutrition Business Journal Releases 2026 Supplement Business Report: U.S. Market Surges Toward $100 Billion Milestone

Nutrition Business Journal Releases 2026 Supplement Business Report, Comprehensive Industry Analysis Driving Growth in Dietary Supplements

Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update

Revenue Increased to $24.9 Million, Net Income Totaled $3.9 Million, and Cash & Marketable Securities Increased to Approximately $31 Million VANCOUVER, BC, June 1, 2026...

World Environment Day: Known water crisis still leaving billions at risk, Hydrachem warns

BILLINGSHURST, England, June 1, 2026 /PRNewswire/ -- As the world prepares to mark World Environment Day (5th June), Hydrachem is calling for renewed focus...

World Environment Day: Known water crisis still leaving billions at risk, Hydrachem warns

BILLINGSHURST, England, June 1, 2026 /PRNewswire/ -- As the world prepares to mark World Environment Day (5th June), Hydrachem is calling for renewed focus...

QVC Group, Inc. Announces Semi-Annual Interest Payment and Regular Additional Distribution on 3.75% Senior Exchangeable Debentures Due 2030

WEST CHESTER, Pa., Aug. 15, 2025 /PRNewswire/ -- QVC Group, Inc. ("QVC Group") (Nasdaq: QVCGA, QVCGP; OTCQB: QVCGB) today announced the payment of a...

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX

TOPDON Releases Professional Grade V3000 Jump Starter with 3000A Peak Current for Large Gasoline and Diesel Engines

BARCELONA, Spain, Aug. 14, 2025 /PRNewswire/ -- TOPDON Europe, a leading provider of professional battery and diagnostic tools, announces the release of the V3000,...

Parents Urged to Make Kids’ Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob

"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ -- In a bold wake-up call...

NativePath Liposomal Vitamin C: Urgent 2025 Consumer Warning on Why Most Vitamin C Pills May Fail — And the 3-in-1 Formula Positioned for Better...

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities. 
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025 
Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTablets

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers